samedan logo
 
 
spacer
home > pmps > winter 2002 > the environmental impact of metered dose inhalers
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Environmental Impact of Metered Dose Inhalers

Asthma and chronic obstructive pulmonary disease (COPD) are chronic lung diseases and are among the leading causes of morbidity and mortality in the Western world. Asthma is a reversible narrowing of the airways, combined with a chronic inflammation. For reasons largely unknown, the incidence of asthma is rapidly rising. The number of patients increases annually, and today approximately five per cent of the population of the US and Europe suffer from this disease (1-4).

COPD is a chronic inflammation and destruction of the airways. There is a progressive, non-reversible loss of lung function which will eventually lead to invalidity and death. COPD usually occurs in elderly people, of which most are smokers or former smokers (5).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Cees Winnips MD, Director of Business Development at SkyePharma AG
Cornelis 'Cees' Winnips is educated and trained as a physician and began his career in the pharmaceutical industry in 1989 with Ciba-Geigy in the Netherlands. After a short period in the medical department, he moved to the commercial side and worked as Group Product Manager.

In 1993, he relocated to Austria to head the marketing department of Ciba Austria. In 1995, he moved to the Ciba/Novartis head office in Basel, Switzerland as Manager of Business Development, and subsequently became International Product Manager for the respiratory franchise. In 1998, he joined SkyePharma as Director of Business Development.

spacer
Cees Winnips
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Emmes launches Orphan Reach™: Emmes’ Rare Disease Center

03rd November, 2021, Rockville, Maryland (USA): Emmes – a full service, global clinical research organization (CRO) – is launching its new center, Orphan Reach™ as a unique ‘rare CRO’.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement